ArticleThe Journal of dermatology2026
Comparative Impact of NSAIDs Versus Acetaminophen on Mortality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective Cohort Study of 2484 Patients From a Nationwide Inpatient Database.
Article in The Journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe and life-threatening mucocutaneous disorders, primarily triggered by medications. Despite the frequent need for antipyretic and analgesic therapy, the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen on clinical outcomes in patients with SJS/TEN remains unclear. This study aimed to compare the effects of NSAIDs and acetaminophen use on in-hospital mortality, infection-related events, and renal outcomes, with particular attention to the presence or absence of chronic kidney disease (CKD). We conducted a retrospective analysis using a nationwide administrative database of over 1200 acute care hospitals in Japan between July 2010 and March 2022. Adult patients diagnosed with SJS or TEN who received either NSAIDs or acetaminophen within the first 5 days of hospitalization were included. Patients who received both drugs or neither were excluded. Among 8301 eligible patients, 2484 met inclusion criteria. Overall mortality did not differ significantly between groups (4.1% vs. 4.6%; risk difference [RD], -0.6%; 95% confidence interval [CI], -2.5% to 1.4%). In patients without CKD, NSAID use was associated with lower mortality (2.6% vs. 4.3%; RD, -1.7%; 95% CI, -3.4% to 0.0%). Conversely, in patients with CKD, acetaminophen use was associated with lower mortality (12.0% vs. 38.2%; RD, 26.2%; 95% CI, 5.0% to 47.4%). In conclusion, NSAID use may be associated with relatively improved survival compared with acetaminophen in patients without CKD, while acetaminophen appears safer in those with CKD, suggesting that renal function may inform the selection of antipyretic or analgesic therapy when such treatment is unavoidable. As both drugs are known causative agents of SJS/TEN, these results should be interpreted with caution. Further studies are warranted to validate these observational findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.